Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Net Income towards Common Stockholders: 2017-2024

Historic Net Income towards Common Stockholders for BridgeBio Pharma (BBIO) over the last 8 years, with Dec 2024 value amounting to -$535.8 million.

  • BridgeBio Pharma's Net Income towards Common Stockholders fell 12.78% to -$182.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$797.1 million, marking a year-over-year decrease of 81.63%. This contributed to the annual value of -$535.8 million for FY2024, which is 16.70% up from last year.
  • Latest data reveals that BridgeBio Pharma reported Net Income towards Common Stockholders of -$535.8 million as of FY2024, which was up 16.70% from -$643.2 million recorded in FY2023.
  • Over the past 5 years, BridgeBio Pharma's Net Income towards Common Stockholders peaked at -$448.7 million during FY2020, and registered a low of -$643.2 million during FY2023.
  • In the last 3 years, BridgeBio Pharma's Net Income towards Common Stockholders had a median value of -$535.8 million in 2024 and averaged -$553.4 million.
  • Per our database at Business Quant, BridgeBio Pharma's Net Income towards Common Stockholders plummeted by 72.20% in 2020 and then climbed by 16.70% in 2024.
  • BridgeBio Pharma's Net Income towards Common Stockholders (Yearly) stood at -$448.7 million in 2020, then dropped by 25.36% to -$562.5 million in 2021, then climbed by 14.46% to -$481.2 million in 2022, then tumbled by 33.67% to -$643.2 million in 2023, then rose by 16.70% to -$535.8 million in 2024.